decisionhealth Newsletters, Coder Pink Sheets - 2004 Issue 12 (December)
AUA tackles CMS on prostate cancer drug pricing
Subscribe or sign in to view the full article.
Article Overview
This piece covers an American Urological Association letter to CMS about Medicare reimbursement changes for prostate cancer drugs. It addresses the broader policy and practice implications for urologists, including concerns about office-based administration, drug acquisition, patient access, and the status of least costly alternative pricing approaches. The article is relevant to urology practices, Medicare billing and reimbursement readers, and anyone tracking drug payment policy changes.
Why This Topic Matters
The article highlights how Medicare payment policy can affect where prostate cancer drugs are obtained and administered, as well as whether practices can continue to stock and provide them in-office. It is useful for understanding the operational and reimbursement concerns raised by specialty physicians when drug pricing methodology changes.
What You Will Learn
- The reimbursement and access concerns raised by urologists regarding prostate cancer drug pricing
- How Medicare payment policy changes may affect office-based drug administration
- The role of least costly alternative pricing in discussions about prostate cancer drugs
- Why physician practice size and inventory costs are relevant to drug access issues
Who Should Read This
- Urologists
- Medical practice administrators
- Medicare billing and reimbursement professionals
- Healthcare policy readers
- Coding and compliance professionals
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com